Eupraxia Pharmaceuticals, Inc. (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals Inc. reported a significant increase in their net loss, jumping from $3.95 million in the first quarter of 2023 to $6.15 million in the same period in 2024. The company’s consolidated balance sheets indicate a healthy boost in total assets from $20.27 million to $36.64 million, thanks in part to a substantial rise in cash holdings. Despite the increased losses, the total shareholders’ equity (deficit) also showed an improvement year-over-year, from $892,326 to $18.1 million.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
